<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Trade Brains Features</provider_name><provider_url>https://tradebrains.in/features</provider_url><author_name>PTI News</author_name><author_url>https://tradebrains.in/features/author/ptinews/</author_url><title>Lupin receives USFDA's nod for generic version of Brivaracetam tablets</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="kqLa68k0fw"&gt;&lt;a href="https://tradebrains.in/features/biz-lupin-3/"&gt;Lupin receives USFDA&#x2019;s nod for generic version of Brivaracetam tablets&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://tradebrains.in/features/biz-lupin-3/embed/#?secret=kqLa68k0fw" width="600" height="338" title="&#x201C;Lupin receives USFDA&#x2019;s nod for generic version of Brivaracetam tablets&#x201D; &#x2014; Trade Brains Features" data-secret="kqLa68k0fw" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><thumbnail_url>https://tradebrains.in/features/wp-content/uploads/2022/02/Lupin-Cover-Image.jpg</thumbnail_url><thumbnail_width>1280</thumbnail_width><thumbnail_height>854</thumbnail_height><description>Pharmaceuticals firm Lupin Ltd on Wednesday said it has received an approval from the US health regulator for the generic version of Brivaracetam tablets used for control of partial onset seizures. The approval by the US Food and Drug Administration (USFDA) is for Brivaracetam tablets of strengths 10 mg, 25 mg, 50 mg, 75 mg, [&hellip;]</description></oembed>
